Novel therapies for bullous keratopathy patients

Cellusion is at the forefront of regenerative medicine, specifically focusing on innovative solutions for corneal treatment through the use of induced pluripotent stem cells (iPSCs). The company is developing corneal endothelial cell substitutes (CECSi) derived from iPSCs to address the significant supply limitations associated with traditional corneal transplants. These limitations include the scarcity of donor corneas, the complexity of the surgical procedure, and the reliance on eye banks for safe distribution. By creating a mass-producible cell substitute, Cellusion aims to alleviate the bottleneck faced by over 10 million patients waiting for corneal transplants worldwide.

The company's approach includes a less invasive cell injection therapy, where a suspension of CECSi cells is administered directly into the eye, making the procedure more accessible for ophthalmologists and less stressful for patients. This method not only simplifies the surgical technique but also eliminates the dependency on donor tissues, allowing for consistent delivery of treatment akin to conventional pharmaceuticals. Through these advancements, Cellusion is committed to enhancing the global presence of Japan's healthcare industry and improving patient outcomes in regenerative medicine.

Japan

Cellusion is committed to pursuing a patient-centric approach at our cutting-edge research and development (R&D) for diseases where regenerative medicine technologies can create a unique value proposition. 

We expand the possibilities of people around the world both physically and mentally.

Cellusion

Company Details